SEATTLE, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the...
Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company,...
New contract to provide broader access to diagnostics in emerging markets Louvain-La-Neuve, Belgium, October 13, 2022 – IBA (Ion Beam Applications S.A.,...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients...
- Three late-breaking presentations to feature emerging evidence of VRDN-001 efficacy and differentiation - - VRDN-001 10mg/kg proof of concept...
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today...
-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application...
WILMETTE, Ill., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and...
Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administrationROCKVILLE, Md., Oct. 12, 2022...
NORCROSS, Ga., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022Study expected to assess VBI-1901...
FLORHAM PARK, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50% of Eligible Cancer Patients Receive...
Integration with the most widely used comprehensive electronic health record will expand clinician and patient access to clonoSEQSEATTLE, Oct. 11,...
Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates Use of Thin Film Freezing...
66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up of 16 monthsFLORHAM PARK, N.J., Oct....